Core Insights - Maze Therapeutics reported positive topline data from the Phase 2 HORIZON trial of MZE829, demonstrating clinical proof-of-concept in patients with broad APOL1-Mediated Kidney Disease (AMKD) [1][3] - The company plans to advance MZE829 into a pivotal program and initiate two Phase 2 trials for MZE782 in phenylketonuria (PKU) and chronic kidney disease (CKD) by 2026 [2][4] - Neil Kumar, Ph.D., has been appointed to the Board of Directors, bringing valuable experience from BridgeBio [2][6] Program Progress and Anticipated Milestones - MZE829 is an oral, small molecule APOL1 inhibitor targeting AMKD, which affects over one million people in the U.S. [3] - The Phase 2 HORIZON trial showed a mean reduction in proteinuria of 35.6% at week 12, with 50% of patients achieving over a 30% reduction [3] - In patients with severe focal segmental glomerulosclerosis (FSGS), the mean reduction in proteinuria was 61.8% [3] - MZE782 targets the solute transporter SLC6A19, with potential applications in PKU and CKD, with trials expected to start by mid-2026 [4] Financial Highlights - As of December 31, 2025, Maze had $360.0 million in cash, cash equivalents, and marketable securities, up from $196.8 million in 2024, providing a cash runway into 2028 [9][21] - Research and development expenses for 2025 were $108.4 million, an increase from $83.5 million in 2024, primarily due to higher clinical trial costs [11] - General and administrative expenses rose to $34.5 million in 2025 from $26.4 million in 2024, reflecting increased personnel-related costs [12] Recent Corporate Developments - The appointment of Neil Kumar to the Board is expected to enhance the company's strategic direction and growth potential [2][6] - Maze achieved a $20 million milestone in its collaboration with Shionogi & Co., Ltd. for MZE001, with potential additional milestone payments of up to $255.0 million [5]

Core Insights - Acrivon Therapeutics is advancing its clinical-stage assets ACR-368 and ACR-2316, showcasing promising preclinical and clinical data in cancer treatment [1][2][6][7] Group 1: ACR-368 Developments - ACR-368, a CHK1/2 inhibitor, is in a registrational-intent Phase 2b study and has shown potent synergy with Topoisomerase 1 inhibitors, which are commonly used in antibody-drug conjugates (ADCs) [1][2] - The FDA has granted Fast Track designation for ACR-368 as a monotherapy for endometrial cancer, based on OncoSignature-predicted sensitivity [6] - ACR-368 treatment can overcome resistance mechanisms to Topo1 inhibitors, leading to enhanced tumor cell killing [2] Group 2: ACR-2316 Developments - ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1, has demonstrated complete and durable tumor regression in preclinical models when combined with anti-PD-L1 checkpoint inhibition [1][2] - Initial data from the Phase 1 trial of ACR-2316 indicates a favorable tolerability profile and initial clinical activity across various solid tumor types, including endometrial cancer and small cell lung cancer (SCLC) [7] Group 3: Acrivon’s AP3 Platform - Acrivon utilizes its proprietary Generative Phosphoproteomics AP3 platform for rational drug design and predictive clinical development, allowing for the identification of therapeutic candidates with high clinical impact [2][4] - The AP3 platform provides extensive data and insights, enabling the rapid design of differentiated compounds and advancing them into clinical trials [4][5] Group 4: Upcoming Presentations - Acrivon will present three posters at the American Association for Cancer Research (AACR) Annual Meeting, highlighting the synergy of ACR-368 with Topo1 inhibitors and the efficacy of ACR-2316 in combination with immune checkpoint inhibitors [1][3]

Core Viewpoint - Kura Oncology, Inc. will report its fourth quarter and full year 2025 financial results on March 5, 2026, before U.S. markets open, followed by a conference call and webcast for discussion [1]. Company Overview - Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline of small molecule drug candidates targeting cancer signaling pathways [3]. - The company has developed KOMZIFTI™, an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and is advancing research in menin inhibition and farnesyl transferase inhibition [3].

Core Viewpoint - Acrivon Therapeutics is advancing its clinical programs and utilizing its proprietary Generative Phosphoproteomics AP3 platform for drug discovery and development, with a focus on precision medicines [3][4]. Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company that develops precision medicines using its Generative Phosphoproteomics AP3 platform, which provides unbiased interpretation and quantification of drug-regulated pathway activity levels [3]. - The AP3 platform generates terabytes of proprietary data and includes tools such as the AP3 Data Portal, Kinase Substrate Relationship Predictor, and Interactome, enabling rapid and differentiated compound design [3]. Clinical Programs - The lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for endometrial cancer, with Fast Track designation from the FDA [4]. - Acrivon is also developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, which has shown favorable tolerability and initial clinical activity in various solid tumor types, including endometrial cancer [5]. - Additionally, Acrivon is advancing ACR-6840, a candidate targeting CDK11, as part of its internally discovered pipeline [5]. Upcoming Events - The company's president and CEO, Peter Blume-Jensen, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1].

Core Insights - Kura Oncology has launched KOMZIFTI™ (ziftomenib), the first and only once-daily oral menin inhibitor approved for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML) [1][10] - The company reported $2.1 million in net product revenue from KOMZIFTI for the initial five-week period following its commercial sale [1][6] - Kura is positioned for significant advancements in 2026 with a robust pipeline of potentially transformative therapies [1][2] Financial Highlights - KOMZIFTI generated $2.1 million in net product revenue from November 21, 2025, to December 31, 2025 [6] - The company expects milestone payments of $195 million from a collaboration agreement with Kyowa Kirin in Q4 2025 [6] - Estimated collaboration revenue for Q4 2025 is between $15 million to $17 million [6] - Kura had $667.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025 [6] Recent Program Highlights - KOMZIFTI received full FDA approval on November 13, 2025, for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation [6] - The drug was added to the NCCN Clinical Practice Guidelines as a Category 2A recommended treatment option for adults with R/R NPM1-m AML [6] - Positive data from the ongoing Phase 1a/1b KOMET-007 trial were presented at the ASH 2025 meeting, showing favorable safety and efficacy in combination with venetoclax and azacitidine [6] - The Phase 3 KOMET-017 trial began in September 2025, evaluating ziftomenib in combination with chemotherapy for newly diagnosed patients [6] Expected 2026 Key Milestones - Accelerate U.S. uptake of KOMZIFTI in R/R NPM1-m AML and drive quarter-over-quarter growth in net product revenue [12] - Present updated data from the KOMET-007 trial and publish combination data in the first half of 2026 [12] - Expand ziftomenib to non-AML indications and advance enrollment in various clinical trials throughout 2026 [12] - Anticipate non-cash collaboration revenue recognition of $45 million to $55 million in 2026 [12]

Core Viewpoint - Acrivon Therapeutics is set to provide clinical data for its lead programs ACR-368 and ACR-2316 on January 8, 2026, highlighting advancements in precision medicine through its proprietary platform [1][4][7] Group 1: Company Overview - Acrivon Therapeutics is a clinical stage biotechnology company focused on discovering and developing precision medicines using its Generative Phosphoproteomics AP3 platform [3] - The AP3 platform enables unbiased interpretation and quantification of drug-regulated pathway activity levels in intact cells, generating terabytes of data for actionable insights [3] - Acrivon aims to overcome traditional drug discovery limitations by rapidly designing differentiated compounds and advancing them into clinical development [3] Group 2: Clinical Programs - ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is currently in a Phase 2b trial for endometrial cancer and has received Fast Track designation from the FDA [4] - The ACR-2316 program, a WEE1/PKMYT1 inhibitor, is in Phase 1 trials, with initial clinical activity and dose proportionality observed in early cohorts [5][7] - Upcoming updates will include interim clinical data from the ACR-368 study and initial data from the ACR-2316 study, along with a new preclinical development candidate [7]

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon Therapeutics utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, allowing for unbiased interpretation of compound-specific pathway activity levels, generating terabytes of data for actionable insights [2] - The AP3 platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, which enhance drug discovery beyond traditional methods [2] Clinical Programs - Acrivon's lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-368 has also received Breakthrough Device designation for its OncoSignature assay to identify suitable patients for treatment [3] - The second clinical asset, ACR-2316, is a WEE1/PKMYT1 inhibitor showing promising early clinical activity and safety in a Phase 1 trial, with initial tumor shrinkage observed [4][6] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data through a conference call and webcast in January 2026, including interim data from the Phase 2b study and the Phase 1 study of ACR-2316 [1][6]

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, allowing for unbiased interpretation of compound-specific pathway activity levels, generating terabytes of data for actionable insights [2] - The platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, which enhance drug discovery beyond traditional methods [2] Clinical Programs - Acrivon's lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-2316, a second clinical stage asset, is a selective WEE1/PKMYT1 inhibitor showing promising preclinical results and is currently in a Phase 1 trial with initial clinical activity observed [4] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data in January 2026, including interim data from the Phase 2b study and initial results from the Phase 1 study of ACR-2316 [6]

Core Viewpoint - Kura Oncology is hosting a virtual analyst and investor event on December 8, 2025, to discuss data on the triplet combination of ziftomenib, venetoclax, and azacitidine for treating acute myeloid leukemia [1][2] Company Overview - Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting cancer signaling pathways and addressing hematologic malignancies and solid tumors [3] - The company has developed KOMZIFTI™, an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia [3]

Core Insights - Kura Oncology has completed its first U.S. commercial sale of KOMZIFTI™ (ziftomenib), marking a significant milestone for the company [1] - The sale triggers a $135 million milestone payment from Kyowa Kirin, expected to be received by Kura before year-end [1] - KOMZIFTI was approved by the U.S. FDA on November 13, 2025, for treating adults with relapsed or refractory NPM1-mutated acute myeloid leukemia [1][2] Company Overview - Kura Oncology is focused on precision medicines for cancer treatment, with a pipeline of small molecule drug candidates targeting cancer signaling pathways [2] - The company is commercializing KOMZIFTI™, a once-daily oral menin inhibitor, and is advancing research in menin inhibition and farnesyl transferase inhibition [2]